Cargando…

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients

Background: New chemotherapy regimens for the treatment of metastatic pancreatic cancer have changed the therapy paradigm. We aimed to assess their impact on the treatment landscape and clinical outcome at our academic institution. Methods: In this single institutional posthoc registry analysis, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kieler, Markus, Unseld, Matthias, Bianconi, Daniela, Schindl, Martin, Kornek, Gabriela V., Scheithauer, Werner, Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141274/ https://www.ncbi.nlm.nih.gov/pubmed/32121198 http://dx.doi.org/10.3390/jcm9030648

Ejemplares similares

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
por: Kieler, Markus, et al.
Publicado: (2017)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
por: Bianconi, Daniela, et al.
Publicado: (2017)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior
por: Bianconi, Daniela, et al.
Publicado: (2022)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
por: Balendran-Braun, Sukirthini, et al.
Publicado: (2021)

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
por: Prager, Gerald W, et al.
Publicado: (2014)

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
por: Unseld, Matthias, et al.
Publicado: (2020)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
por: Kieler, Markus, et al.
Publicado: (2019)

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology
por: Prager, Gerald W., et al.
Publicado: (2019)

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
por: Unseld, Matthias, et al.
Publicado: (2018)

Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease
por: Kieler, Markus, et al.
Publicado: (2016)

Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
por: Scheithauer, Werner, et al.
Publicado: (2019)

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
por: Bianconi, Daniela, et al.
Publicado: (2015)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis
por: Zhang, Shuisheng, et al.
Publicado: (2018)

Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
por: Hejna, M., et al.
Publicado: (1998)

Clinically Meaningful Responses to Sequential Gemcitabine-Based Chemotherapy Regimens in a Patient with Metastatic Pancreatic Cancer
por: Klimant, Eiko, et al.
Publicado: (2013)

Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
por: Posch, Doris, et al.
Publicado: (2016)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer
por: Giordano, Guido, et al.
Publicado: (2023)

Side effects during chemotherapy predict tumour response in advanced colorectal cancer
por: Schuell, B, et al.
Publicado: (2005)

Dilemma of first line regimens in metastatic pancreatic adenocarcinoma
por: Ghosn, Marwan, et al.
Publicado: (2016)

Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
por: Domadia, Kshitij, et al.
Publicado: (2021)

CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior
por: Poettler, Marina, et al.
Publicado: (2013)

Kidney Function Worsening Is Linked to Parenteral-Nutrition-Dependent Survival in Palliative Care Patients
por: Kum, Lea, et al.
Publicado: (2022)

Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer
por: Hale, J P, et al.
Publicado: (2002)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin
por: Kornek, G V, et al.
Publicado: (2000)

Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer
por: Wu, Lili, et al.
Publicado: (2020)

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies
por: Gaiger, Alexander, et al.
Publicado: (2022)

Personalization of Chemotherapy for Metastatic Pancreatic Cancer
por: Sasahara, Yuriko (Ito), et al.
Publicado: (2014)

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer
por: Bartl, Thomas, et al.
Publicado: (2023)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

C-reactive protein and white blood cell count are adverse prognostic markers for patients with advanced cancer on parenteral nutrition in a palliative care unit setting: A retrospective cohort study
por: Kieler, Markus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_15kpb6gabn0kr2u8n3kdpaknla